Basket | Login | Register

 
 
 
 

European Alzheimer's Disease Consortium

Our partners


Background

The EADC is a network of European centres of excellence working in the field of Alzheimer's disease. It provides a setting in which to increase the basic scientific understanding of and to develop ways to prevent, slow or ameliorate the primary and secondary symptoms of Alzheimer's disease. This is done by facilitating large Europe wide research studies.

Alzheimer Europe works closely together with EADC. Within the framework of the various EADC projects, the role of Alzheimer Europe is to represent the interests of people with dementia, their families and their carers.


Main activities

  • Biannual meeting of steering committee and Special Interest Groups
  • Update on EADC activities
  • Decide future projects and new centres
  • Presentation of results
  • Communication with American counterparts to avoid duplication of work and discuss collaboration.

Research projects

Each project will use the expertise of the Consortium for advise, data management and ethics and public awareness. Research projects will be funded by:

  • Public funding at either national or European level
  • A combination of public and industry funding
  • Pharmaceutical industry funding.

This type of study will comply with EADC guidelines about collaboration with the pharmaceutical industry. Except in exceptional circumstances a maximum of one study per year will be undertaken in this category by the consortium.

Two studies are actually on-going: ICTUS and DESCRIPA

ICTUS - Impact of treatment with Anticholinesterase Inhibitors (AChE I) on Europeans with Alzheimer's Disease (AD)

is a prospective 2 years observational study which co-ordinates the centralisation of patient data available within the study's individual centres.

The primary objective of ICTUS is to determine whether treatment with AChE I changes the pattern of institutionalisation in European AD patients. The secondary objectives are to determine:

  • The natural history of AD in Europe (cognitive impairment, and non cognitive domains of activities of daily living, behavioral disorders, and dependency).
  • Identification of patient subgroups which respond differentially to AChE I treatment, using neuro-imaging.
  • The impact of AChE I treatment on natural history and the caregiver burden of AD, on the financial burden of AD in Europe.
  • The predictive factors for decline using hospitalisation and institutionalisation as markers of decline in AD.

DESCRIPA - Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease

The primary goal of the project will be to perform a concerted action in order to reach an evidence-based European consensus on the identification of subjects with AD in the predementia stage.

The secondary goals of the project will be the development of diagnostic criteria for predementia AD in a clinical setting and the development of screening guidelines for predementia AD in the general population.


Contact details

European Alzheimer's Disease Consortium
CHU La Grave-Casselardit, Department of Internal and Geriatrics Medicine
170 Avenue de Casselardit
31300-Toulouse
France
Tel: +33 - 5 - 61 77 76 06
Fax : +33 - 5 - 61 49 71 09
Website: www.eadc.info

 

 
 

Last Updated: Tuesday 20 March 2012

 

 
 

Options

  • Send this page to a friend